<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03759093</url>
  </required_header>
  <id_info>
    <org_study_id>2015/00280</org_study_id>
    <nct_id>NCT03759093</nct_id>
  </id_info>
  <brief_title>CURATE.AI Optimized Modulation for Multiple Myeloma</brief_title>
  <official_title>Phenotypic Personalized Medicine: Systematically Optimized Combination Therapy in Multiple Myeloma Using CURATE.AI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National University Hospital, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National University of Singapore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National University Hospital, Singapore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical trial applying CURATE.AI, a Phenotypic Precision Medicine (PPM) platform, to&#xD;
      Bortezomib, Thalidomide, Cyclophosphamide and Lenalidomide dosing in multiple myeloma&#xD;
      patients to show improvement in response.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In conventional combination chemotherapy, drug doses are typically determined using dose&#xD;
      escalation to reach a maximum tolerated dose (MTD) or via dose expansion to identify suitable&#xD;
      regimen administration guideline, and the combinations are subsequently administered at fixed&#xD;
      doses. During the course of treatment, the patient's response to therapy evolves and changes&#xD;
      due to the time-dependent, dose dependent, and patient-specific nature of drug synergy and&#xD;
      resulting efficacy and tolerability. To overcome this challenge, we have developed CURATE.AI,&#xD;
      a Phenotypic Precision Medicine (PPM) platform, which has been clinically validated and used&#xD;
      to prospectively optimize patient liver transplant immunosuppression, and tuberculosis&#xD;
      therapy, among other indications. In this study, CURATE.AI may improve patient response by&#xD;
      providing dose recommendations for Bortezomib, Thalidomide, Cyclophosphamide and Lenalidomide&#xD;
      to the clinical team over the course of the patient's treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 10, 2023</start_date>
  <completion_date type="Anticipated">September 10, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 10, 2025</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>Up to 16 weeks or at the end of cycle 4 of treatment (each cycle is 28 days)</time_frame>
    <description>Complete response (CR), or stringent complete response (sCR), or very good partial response (VGPR), or partial response (PR) based on IMWG criteria at the end of cycle 4</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)</measure>
    <time_frame>Up to 16 weeks or at the end of cycle 4 of treatment (each cycle is 28 days)</time_frame>
    <description>Occurrence of adverse events throughout the study, graded via Common Terminology Criteria for Adverse Events (CTCAE) v 4.03 criteria.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dosing of VCD(bortezomib, cyclophosphamide,dexamethasone), VTD (bortezomib,thalidomide, dexamethasone), or VRD (Bortezomib, Lenalidomide, Dexamethasone) combinations according to standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CURATE.AI-guided dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CURATE.AI optimized modulation of bortezomib and cyclophosphamide dosages in the VCD (bortezomib, cyclophosphamide, dexamethasone), bortezomib and thalidomide in the VTD (bortezomib, thalidomide, dexamethasone) or bortezomib and lenalidomide in the VRD (bortezomib, lenalidomide, dexamethasone) combinations</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team</description>
    <arm_group_label>Standard of Care</arm_group_label>
    <other_name>Velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team</description>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team</description>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CURATE.AI-Guided dosage modulation</intervention_name>
    <description>CURATE.AI-guided modulation of Velcade and Cyclophosphamide dosages for VCD regimen, Velcade and Thalidomide dosages for VTD regimen, and Velcade and Lenalidomide dosages for VRD regimen</description>
    <arm_group_label>CURATE.AI-guided dosing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
    <description>Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team</description>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Dose in a range of 0.7,1.0,1.3 mg/m2 subcutaneous (SC) injection on Day 1, 8, 15 ,22 for cycles 1 to 4 , as determined and guided by CURATE.AI and approved by the clinical care team</description>
    <arm_group_label>CURATE.AI-guided dosing</arm_group_label>
    <other_name>Velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Dosing in a range of 100, 300, 500 mg PO on Day 1, 8, 15, 22 for cycles 1 to 4 as determined and guided by CURATE.AI and approved by the clinical care team.</description>
    <arm_group_label>CURATE.AI-guided dosing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
    <description>Dose in a range of 50-200mg PO on day 1-28 for cycles 1 to 4 as determined and guided by CURATE.AI and approved by the clinical care team.</description>
    <arm_group_label>CURATE.AI-guided dosing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>40 mg PO on Day 1 ,8 , 15, 22 for cycles 1 to 4, as determined and guided by the clinical care team according to standard of care</description>
    <arm_group_label>CURATE.AI-guided dosing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team</description>
    <arm_group_label>Standard of Care</arm_group_label>
    <other_name>Revlimid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Dose in a range of 5-25mg PO on day 1-21 for cycles 1 to 4, as determined and guided by CURATE.AI and approved by the clinical care team.</description>
    <arm_group_label>CURATE.AI-guided dosing</arm_group_label>
    <other_name>Revlimid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Multiple myeloma diagnosed according to standard criteria, without prior anti-myeloma&#xD;
             treatment at study entry. Both transplant eligible and ineligible patients may be&#xD;
             included.&#xD;
&#xD;
          2. Patients must have evaluable multiple myeloma with at least one of the following&#xD;
             (within 21 days of starting treatment)&#xD;
&#xD;
               1. Serum M-protein ≥ 0.5g/dL, or&#xD;
&#xD;
               2. In subjects without detectable serum M-protein, Urine M-protein ≥ 200mg/24 hour,&#xD;
                  or serum free light chai (sFLC) &gt; 100mg/L (involved light chain) and an abnormal&#xD;
                  kappa/Lambda ratio&#xD;
&#xD;
          3. Males and females ≥ 18 years of age or &gt; country's legal age for adult consent&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2&#xD;
&#xD;
          5. Patients must meet the following clinical laboratory criteria with 21 days of starting&#xD;
             treatment:&#xD;
&#xD;
               1. Absolute neutrophil count (ANC) ≥ 1,000/mm3 and platelet ≥ 50,000/mm3 (≥&#xD;
                  30,000/mm3 if myeloma involvement in the bone marrow is &gt;50%)&#xD;
&#xD;
               2. Total bilirubin ≤ 1.5 x the upper limit of the normal range (ULN). Alanine&#xD;
                  aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x ULN.&#xD;
&#xD;
               3. Calculated creatinine clearance ≥ 30mL/min or creatinine &lt; 3mg/dL.&#xD;
&#xD;
          6. Written informed consent in accordance with federal, local and institutional&#xD;
             guidelines&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Female patients who are lactating or pregnant&#xD;
&#xD;
          2. Multiple Myeloma of IgM subtype&#xD;
&#xD;
          3. Glucocorticoid therapy (prednisolone &gt; 30mg/day or equivalent) within 14 days prior to&#xD;
             informed consent obtained&#xD;
&#xD;
          4. POEMS syndrome&#xD;
&#xD;
          5. Plasma cell leukaemia or circulating plasma cells ≥ 2 x 109/L&#xD;
&#xD;
          6. Waldenstrom's Macroglobulinaemia&#xD;
&#xD;
          7. Patients with known amyloidosis&#xD;
&#xD;
          8. Chemotherapy with approved or investigation anticancer therapeutics within 21 days&#xD;
             prior to starting bortezomib treatment&#xD;
&#xD;
          9. Focal radiation therapy within 7 days prior to start of treatment. Radiation therapy&#xD;
             to an extended field involving a significant volume of bone marrow within 21 days&#xD;
             prior to start of treatment&#xD;
&#xD;
         10. Immunotherapy (excluding steroids) 21 days prior to start of treatment&#xD;
&#xD;
         11. Major surgery (excluding kyphoplasty) within 28 days prior to start of treatment&#xD;
&#xD;
         12. Active congestive heart failure (New York Heart Association [NYHA] Class III or IV),&#xD;
             symptomatic ischaemia, or conduction abnormalities uncontrolled by conventional&#xD;
             intervention. Myocardial infarction within 4 months prior to informed consent obtained&#xD;
&#xD;
         13. Known HIV seropositive, hepatitis C infection, and/or hepatitis B (except for patients&#xD;
             with hepatitis B surface antigen or core antibody receiving and responding to&#xD;
             antiviral therapy directed at hepatitis B: these patients are allowed)&#xD;
&#xD;
         14. Patients with known cirrhosis&#xD;
&#xD;
         15. Second malignancy within the past 3 years except:&#xD;
&#xD;
               1. Adequately treated basal cell or squamous cell skin cancer&#xD;
&#xD;
               2. Carcinoma in situ of the cervix&#xD;
&#xD;
               3. Breast carcinoma in situ with full surgical resection&#xD;
&#xD;
         16. Patients with myelodysplastic syndrome&#xD;
&#xD;
         17. Patients with steroid, cyclophosphamide, bortezomib, lenalidomide or thalidomide&#xD;
             hypersensitivity&#xD;
&#xD;
         18. Patients with a calculated creatinine clearance less than 30ml/min by the Cockroft&#xD;
             Galt method.&#xD;
&#xD;
         19. Prior treatment with Bortezomib&#xD;
&#xD;
         20. Contraindication to any of the required concomitant drugs or supportive treatments&#xD;
&#xD;
         21. Any clinically significant medical disease or psychiatric condition that, in the&#xD;
             investigator's opinion, may interfere with protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wee Joo Chng, Prof</last_name>
    <phone>67795555</phone>
    <email>mdccwj@nus.edu.sg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sanjay de Mel, Dr</last_name>
    <phone>67795555</phone>
    <email>sanjay_widanalage@nuhs.edu.sg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wee Joo Chng, Prof</last_name>
      <phone>67795555</phone>
      <email>mdccwj@nus.edu.sg</email>
    </contact>
    <contact_backup>
      <last_name>Sanjay de Mel, Dr</last_name>
      <phone>67795555</phone>
      <email>sanjay_widanalage@nuhs.edu.sg</email>
    </contact_backup>
    <investigator>
      <last_name>Wee Joo Chng, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Edward Chow, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dean Ho, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sanjay de Mel, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Melissa Ooi, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <reference>
    <citation>Pantuck, A.J., Lee, D.K., Kee, T., Wang, P., Lakhotia, S., Silverman, M.H., Mathis, C., Drakaki, A., Belldegrun, A.S., Ho, C.M. and Ho, D., 2018. Modulating BET Bromodomain Inhibitor ZEN-3694 and Enzalutamide Combination Dosing in a Metastatic Prostate Cancer Patient Using CURATE. AI, an Artificial Intelligence Platform. Advanced Therapeutics, 1(6), p.1800104.</citation>
  </reference>
  <verification_date>August 2023</verification_date>
  <study_first_submitted>November 20, 2018</study_first_submitted>
  <study_first_submitted_qc>November 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2018</study_first_posted>
  <last_update_submitted>August 31, 2023</last_update_submitted>
  <last_update_submitted_qc>August 31, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National University Hospital, Singapore</investigator_affiliation>
    <investigator_full_name>Haematology-Oncology</investigator_full_name>
    <investigator_title>Professor Chng Wee Joo</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03759093
org study id: 2015/00280
nct id: NCT03759093
lead sponsor: 
collaborator: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
is us export: No
Clinical trial applying CURATE.AI, a Phenotypic Precision Medicine (PPM) platform, to
      Bortezomib, Thalidomide, Cyclophosphamide and Lenalidomide dosing in multiple myeloma
      patients to show improvement in response.
In conventional combination chemotherapy, drug doses are typically determined using dose
      escalation to reach a maximum tolerated dose (MTD) or via dose expansion to identify suitable
      regimen administration guideline, and the combinations are subsequently administered at fixed
      doses. During the course of treatment, the patient's response to therapy evolves and changes
      due to the time-dependent, dose dependent, and patient-specific nature of drug synergy and
      resulting efficacy and tolerability. To overcome this challenge, we have developed CURATE.AI,
      a Phenotypic Precision Medicine (PPM) platform, which has been clinically validated and used
      to prospectively optimize patient liver transplant immunosuppression, and tuberculosis
      therapy, among other indications. In this study, CURATE.AI may improve patient response by
      providing dose recommendations for Bortezomib, Thalidomide, Cyclophosphamide and Lenalidomide
      to the clinical team over the course of the patient's treatment.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: Single (Participant)
measure: Response rate
time frame: Up to 16 weeks or at the end of cycle 4 of treatment (each cycle is 28 days)
description: Complete response (CR), or stringent complete response (sCR), or very good partial response (VGPR), or partial response (PR) based on IMWG criteria at the end of cycle 4
measure: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)
time frame: Up to 16 weeks or at the end of cycle 4 of treatment (each cycle is 28 days)
description: Occurrence of adverse events throughout the study, graded via Common Terminology Criteria for Adverse Events (CTCAE) v 4.03 criteria.
arm group label: Standard of Care
arm group type: Active Comparator
description: Dosing of VCD(bortezomib, cyclophosphamide,dexamethasone), VTD (bortezomib,thalidomide, dexamethasone), or VRD (Bortezomib, Lenalidomide, Dexamethasone) combinations according to standard of care
arm group label: CURATE.AI-guided dosing
arm group type: Experimental
description: CURATE.AI optimized modulation of bortezomib and cyclophosphamide dosages in the VCD (bortezomib, cyclophosphamide, dexamethasone), bortezomib and thalidomide in the VTD (bortezomib, thalidomide, dexamethasone) or bortezomib and lenalidomide in the VRD (bortezomib, lenalidomide, dexamethasone) combinations
intervention type: Drug
intervention name: Bortezomib
description: Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
arm group label: Standard of Care
other name: Velcade
intervention type: Drug
intervention name: Cyclophosphamide
description: Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
arm group label: Standard of Care
intervention type: Drug
intervention name: Dexamethasone
description: Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
arm group label: Standard of Care
intervention type: Other
intervention name: CURATE.AI-Guided dosage modulation
description: CURATE.AI-guided modulation of Velcade and Cyclophosphamide dosages for VCD regimen, Velcade and Thalidomide dosages for VTD regimen, and Velcade and Lenalidomide dosages for VRD regimen
arm group label: CURATE.AI-guided dosing
intervention type: Drug
intervention name: Thalidomide
description: Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
arm group label: Standard of Care
intervention type: Drug
intervention name: Bortezomib
description: Dose in a range of 0.7,1.0,1.3 mg/m2 subcutaneous (SC) injection on Day 1, 8, 15 ,22 for cycles 1 to 4 , as determined and guided by CURATE.AI and approved by the clinical care team
arm group label: CURATE.AI-guided dosing
other name: Velcade
intervention type: Drug
intervention name: Cyclophosphamide
description: Dosing in a range of 100, 300, 500 mg PO on Day 1, 8, 15, 22 for cycles 1 to 4 as determined and guided by CURATE.AI and approved by the clinical care team.
arm group label: CURATE.AI-guided dosing
intervention type: Drug
intervention name: Thalidomide
description: Dose in a range of 50-200mg PO on day 1-28 for cycles 1 to 4 as determined and guided by CURATE.AI and approved by the clinical care team.
arm group label: CURATE.AI-guided dosing
intervention type: Drug
intervention name: Dexamethasone
description: 40 mg PO on Day 1 ,8 , 15, 22 for cycles 1 to 4, as determined and guided by the clinical care team according to standard of care
arm group label: CURATE.AI-guided dosing
intervention type: Drug
intervention name: Lenalidomide
description: Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
arm group label: Standard of Care
other name: Revlimid
intervention type: Drug
intervention name: Lenalidomide
description: Dose in a range of 5-25mg PO on day 1-21 for cycles 1 to 4, as determined and guided by CURATE.AI and approved by the clinical care team.
arm group label: CURATE.AI-guided dosing
other name: Revlimid
criteria: 
gender: All
minimum age: 21 Years
maximum age: 99 Years
healthy volunteers: No
last name: Wee Joo Chng, Prof
phone: 67795555
email: mdccwj@nus.edu.sg
last name: Sanjay de Mel, Dr
phone: 67795555
email: sanjay_widanalage@nuhs.edu.sg
facility: 
status: Recruiting
contact: 
contact backup: 
investigator: 
investigator: 
investigator: 
investigator: 
investigator: 
country: Singapore
citation: Pantuck, A.J., Lee, D.K., Kee, T., Wang, P., Lakhotia, S., Silverman, M.H., Mathis, C., Drakaki, A., Belldegrun, A.S., Ho, C.M. and Ho, D., 2018. Modulating BET Bromodomain Inhibitor ZEN-3694 and Enzalutamide Combination Dosing in a Metastatic Prostate Cancer Patient Using CURATE. AI, an Artificial Intelligence Platform. Advanced Therapeutics, 1(6), p.1800104.
responsible party type: Principal Investigator
investigator affiliation: National University Hospital, Singapore
investigator full name: Haematology-Oncology
investigator title: Professor Chng Wee Joo
mesh term: Multiple Myeloma
mesh term: Neoplasms, Plasma Cell
mesh term: Thalidomide
mesh term: Dexamethasone
mesh term: Dexamethasone acetate
mesh term: Cyclophosphamide
mesh term: Lenalidomide
mesh term: Bortezomib
mesh term: BB 1101
sharing ipd: No